Key Indicators of Value and Success in a Life Sciences Company

04 December 2007 Past Event

In any due diligence process, knowing the assumptions that drive the value estimate and the methodology used to balance anticipated investments, risks, and rewards will allow for a company to adjust the diligence review accordingly. This discussion will cover:

  • Approaches for developing valuation and valuation assumptions for in-licensing, M&A, IPO, and R&D
  • Evaluating the future impact of key items when reviewing a biotech IP portfolio
  • Identifying factors that executives use to arrive at a starting value, and then quantifying the deductions depending on the results of the IP due diligence
  • Valuation methodologies used for early-stage vs. late-stage products

Panelists include: Gregg Alton, Senior Vice President and General Counsel, Gilead Sciences, Inc.; Doug Crawford, Associate Executive Director, QB3; Doug Sheehy, Vice President & General Counsel, Codexis, Inc.; and Paul Stewart, Partner, Foley.

Insights

Blockchain: A Tool With a Future in Healthcare
18 July 2019
Health Care Law Today
A Review of Recent Whistleblower Developments
18 July 2019
Legal News: Whistleblower Developments
Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Does The U.S. Need STRONGER Patents?
16 July 2019
PTAB Trial Insights
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ